Skip to content
Precision for Medicine
Press Release

Precision Continues Asia-Pacific Expansion with Opening of Japan Office

iStock-1460099874 (1)

Clinical Trial Monitoring with Precision

Navigating the path to Precision in every study.
At Precision for Medicine, our Clinical Trial Monitoring strategies blend the art of oversight with the capabilities of innovative technologies. With an unwavering commitment to patient safety, data integrity, and trial efficiency, we will enhance each phase of your clinical development journey. We transform challenges into milestones, guiding your journey to success with unmatched precision

Principles of Precision in Clinical Trial Monitoring

At Precision for Medicine, our Clinical Research Associates (CRAs) serve as the linchpin between trials and triumph. Grounded in a philosophy that intertwines the safety of patients with the sanctity of data, our CRAs embody a suite of principles to diligently advance your trial’s objectives. Through proactive site management, effective communication, and unwavering compliance, they ensure each monitored site resonates with the rigor and care that define Precision’s approach to clinical oversight. Our commitment extends beyond standard practices, nurturing a culture of training and mentorship to foster growth and excellence in clinical monitoring.

  • iStock-1442379947

    Patient Safety First

    Our CRAs prioritize patient well-being, meticulously monitoring safety protocols and ensuring prompt reporting of adverse events to safeguard participants.
  • iStock-1469776926 (2)

    Proactive Site Management

    Vigilant and forward-thinking, our CRAs embrace site responsibility, preemptively addressing risks and streamlining solutions for challenges ahead
  • iStock-1759892670

    Effective Communication

    Timely dissemination of site updates and swift report filing keep all stakeholders informed and engaged with the latest trial developments.
  • iStock-1468267123

    Compliance & Protocol Adherence

    With a rigorous commitment to GCP and regulatory standards, our CRAs ensure protocol fidelity and comprehensive documentation integrity.
  • iStock-1353123922

    Training & Mentorship

    We invest in continuous training and mentorship to empower our CRAs with the expertise and confidence to excel in the field.
  • iStock-1455449749

    Data Integrity Focus

    The cornerstone of our mission is to safeguard the precision and integrity of study data, fueling reliable outcomes and decisive insights.

Precision in Clinical Monitoring strategies

Precision is adept in the distinct demands of early and late-phase clinical trials, particularly within the realms of Oncology and Rare Disease research. Each phase carries unique monitoring considerations, such as the intensive oversight required during the initial dosing of Phase I studies. Precision tailors monitoring approaches to your trial's design, collaborating with you to determine the monitoring intensity required for optimal data quality and cost-efficiency.
  • SDV Scenarios
  • Risk-based Monitoring
  • Centralized Monitoring
  • Tailored Source Data Verification Approaches

    Precision recognizes that a one-size-fits-all approach does not apply when it comes to Source Data Verification (SDV). Depending on the design and phase of your trial, different SDV strategies—be it 100%, reduced or targeted SDV—can be implemented to maximize data quality while optimizing the allocation of monitoring resources. With our nuanced understanding, we craft SDV monitoring plans that support the depth of data scrutiny required, whether that involves comprehensive verification or a targeted review aligned with specific data risks and study endpoints. By selecting the most suitable SDV method, Precision enhances the integrity of your data and the efficiency of your trial monitoring.
    Patient Data Review
  • Enhancing Clinical Oversight with Risk-Based Monitoring

    At Precision, we embrace a data-centric approach to Risk-Based Monitoring (RBM). By identifying the critical data and how it is collected, we identify potential risks and develop robust strategies to proactively secure the data, enabling our CRAs to focus their efforts where it's most needed. This method not only streamlines the monitoring process but also allocates resources more effectively so that critical trial aspects receive the attention required without undue expenditure. Utilizing advanced analytical tools, such as Precision's Clarity alongside industry-standard platforms like Medidata CTMS, our RBM strategies are designed to safeguard the integrity of your trial data while optimizing the monitoring workload.

    Risk Based Monitoring RBM
  • Enhanced Centralized Monitoring with Precision

    Precision's Centralized Monitoring team leverages our proprietary Clarity clinical intelligence suite to provide a comprehensive review of aggregate data, identifying outliers, trends, and safety signals. Our strategic approach reduces the need for frequent onsite visits by utilizing powerful analytics and dynamic data visualization, augmented by our cross-functional and integrated data review process. This enables Precision to optimize site performance and data integrity, supporting a streamlined SDV/SDR strategy.

    Explore
    Remote Monitoring
iStock-1402843850 (1)

Transforming clinical trials through patient centricity

The emphasis on patient centricity and decentralized clinical trials (DCTs) is more than a trend—it’s a transformative shift towards respecting and accommodating the real-world contexts of patients and their caregivers. Precision for Medicine champions this shift, drawing from our rich experience across oncology and rare diseases, to design trials that are as considerate as they are scientifically rigorous. By thoughtfully incorporating patient lifestyles and symptoms into trial designs, we ensure participation is not only viable but also meaningful for patients and caregivers alike. Our strategies embody our commitment to making trials more patient-centric, from pediatric to adult populations, offering a smoother and more inclusive research journey. Discover how our innovative approaches in patient recruitment (HL) and DCTs (HL) are making a difference.

Experts in Complex Diseases and Advanced Therapies

We recognize the patient journey throughout the development process. Our mission is to assist our partners in delivering innovative treatments to patients. Leverage our deep expertise in these therapeutic areas to advance your clinical goals.

Precision insights in Clinical Monitoring and beyond

Stay at the forefront of research with Precision’s blog, featuring key updates and insights on clinical monitoring, case studies, and more

Read: What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs

Clinical Trials - Regulatory

What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=195804116748, hs_child_table_id=0, hs_updated_at=1764696930757, hs_published_at=1772549698856, description=John is an experienced regulatory affairs consultant with more than 15 years of professional experience in drug development. He brings a proven track record in providing regulatory strategy, regulatory document development and review, and liaising with regulatory authorities., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/John%20McIntyre.png',altText='John McIntyre',fileId=201584594055}, lastname=McIntyre, PhD, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757515873736, hs_is_edited=false, hs_deleted_at=0, name=John, job=Senior Director, Regulatory Strategy, slug=john-mcintyre, hs_updated_by_user_id=26433386}, second={hs_id=195821592097, hs_child_table_id=0, hs_updated_at=1757598947835, hs_published_at=1772549698856, description=An expert in hematology and oncology and a veteran of the FDA with almost nine years of experience, culminating as a Deputy Director for the Division of Hematologic Malignancies 2. Possesses a profound understanding of regulatory strategy, particularly in the development of CAR-T cell therapies, bispecifics and T-cell engagers. Spearheaded initiatives to develop novel endpoints in blood cancer such as minimal residual disease (MRD) in lymphoma and chronic lymphocytic leukemia (CLL.), avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Nicholas%20Richardson.png',altText='Nicholas Richardson',fileId=195817841672}, linkedin=https://www.linkedin.com/in/nicholas-richardson-do-mph-049784113/, team=[{id=163080551773, name='Clinical Solutions Leadership'}], lastname=Richardson, DO, MPH, hs_initial_published_at=1757528527317, hs_created_by_user_id=51739740, hs_created_at=1757528274871, hs_is_edited=false, hs_deleted_at=0, name=Nicholas, job=Vice President, Clinical Development, slug=nicholas-richardson-clinical-solutions, hs_updated_by_user_id=26433386}, third={hs_id=178046423372, hs_child_table_id=0, hs_updated_at=1754641388766, hs_published_at=1772549698856, description=Rosamund (Roz) Round is a seasoned expert in patient engagement and innovation bringing over 20 years of experience. She is focused on listening to and learning from patients and care partners to understand how to better improve trial access and experience. Roz successfully built and led decentralized clinical trials service through the pandemic and is now addressing the implementation of AI across various aspects of clinical research. She has a strong focus on diversity, equity, and inclusion (DEI) to drive health equity in clinical research. Roz holds an MSc in Health Psychology, studied Psychology and Immunology at Harvard University, and is a recognized thought leader with an extensive portfolio of publications, conference presentations, webinars, and vlogs., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Round-Rosamund.png',altText='Round-Rosamund',fileId=194123714174}, lastname=Round, hs_initial_published_at=1725972637852, hs_created_by_user_id=51739740, hs_created_at=1725972446462, hs_is_edited=false, hs_deleted_at=0, name=Rosamund, job=Vice President, PAtient Engagement & Innovation, slug=rosamund-round, hs_updated_by_user_id=26433386}})
  • John M. avatar Nicholas R. avatar Rosamund R. avatar
  • John M.

    Nicholas R.

    Rosamund R.

Discover
Read: Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market

Oncology

Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=208638641305, hs_child_table_id=0, hs_updated_at=1772549693775, hs_published_at=1772549698856, description=Lisa is a Director, Project Management who has been with Precision since Jan 2019. Lisa has over 18 years of clinical research experience, with a proven track record in leading cross-functional teams across programs of studies. Lisa is a collaborative communicator capable of cultivating key relationships focused on customer satisfaction. In 2018, Lisa was granted the CEO Excellence Award for exceptional project management., avatar=Image{width=378,height=339,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Lisa%20Lopez_Headshot.jpg',altText='Lisa Lopez_Headshot',fileId=208044988231}, lastname=Lopez, hs_initial_published_at=1772549698856, hs_created_by_user_id=26433386, hs_created_at=1772549635830, hs_is_edited=false, hs_deleted_at=0, name=Lisa, job=Director, Project Management, slug=lisa-lopez, hs_updated_by_user_id=26433386}, second={hs_id=208600974006, hs_child_table_id=0, hs_updated_at=1772549671531, hs_published_at=1772549698856, description=Adrien (Ash) Mtibaa, MD is a clinical research leader with 10+ years of experience in global clinical trials and deep expertise in Site Start‑Up (SSU). Currently Manager, Site Start‑Up at Precision for Medicine, he leads and mentors global SSU teams with a strong focus on process improvement, SSU strategy, leadership influence, and line management. A trained Medical Doctor, Adrien brings a pragmatic, results‑driven approach to driving activation readiness, operational excellence, and cross‑functional alignment across multi‑regional studies., avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Adrien%20Mtibaa%2c%20MD.jpg',altText='Adrien Mtibaa, MD',fileId=208642032927}, lastname=Mtibaa, MD, hs_initial_published_at=1772549611983, hs_created_by_user_id=26433386, hs_created_at=1772488816847, hs_is_edited=false, hs_deleted_at=0, name=Adrien, job=Manager, Site Start Up, slug=adrien-mtibaa, hs_updated_by_user_id=26433386}, third={}})
  • Lisa L. avatar

    Lisa L.

  • Adrien M. avatar

    Adrien M.

Discover

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore